By Counterforce Health Team in Ocrevus (ocrelizumab) —

Myths vs. Facts: Getting Ocrevus (ocrelizumab) Covered by Blue Cross Blue Shield in Washington

Answer Box: Getting Ocrevus Covered by Blue Cross Blue Shield in Washington

Eligibility: Ocrevus requires prior authorization from Blue Cross Blue Shield Washington plans. New requests effective March 10, 2025 require failure of 2+ disease-modifying therapies including natalizumab for relapsing MS, or confirmed primary progressive MS diagnosis under age 55.

Fastest path: Have your neurologist submit prior authorization with documented DMT failures and clinical notes. Most denials stem from incomplete step therapy documentation, not medical necessity.

First step today: Call your Blue Cross Blue Shield member services (number on your card) to confirm your plan's specific prior authorization requirements and obtain the current form.

Table of Contents

  1. Why Myths About Ocrevus Coverage Persist
  2. Common Myths vs. Facts
  3. What Actually Influences Approval
  4. Avoid These Preventable Mistakes
  5. Quick Action Plan: Three Steps to Do Today
  6. Appeals Process in Washington
  7. Resources and Forms

Why Myths About Ocrevus Coverage Persist

Confusion about Ocrevus (ocrelizumab) coverage with Blue Cross Blue Shield in Washington often stems from the complexity of multiple sclerosis treatment pathways and frequently changing insurance policies. With Blue Cross Blue Shield Washington updating their Ocrevus criteria as recently as March 2025, even healthcare providers struggle to keep current with requirements.

The medication's unique position as the first FDA-approved treatment for primary progressive MS adds another layer of complexity. Patients and families often receive conflicting information from online forums, insurance representatives who aren't familiar with specialty drugs, and well-meaning but outdated advice from other patients.

Understanding the facts can save you months of delays and unnecessary denials.

Common Myths vs. Facts

Myth 1: "If my neurologist prescribes Ocrevus, Blue Cross Blue Shield has to cover it"

Fact: Prior authorization is required regardless of your doctor's prescription. Blue Cross Blue Shield Washington requires prior authorization for Ocrevus to ensure clinical appropriateness and cost-effectiveness. Your neurologist must demonstrate you meet specific criteria before coverage begins.

Myth 2: "I can start with Ocrevus as my first MS treatment"

Fact: For relapsing forms of MS, Blue Cross Blue Shield Washington requires step therapy - you must have failed, had contraindications to, or been intolerant of more than 2 disease-modifying therapies, including natalizumab and at least one other agent like glatiramer or interferon beta.

Myth 3: "The new 2025 rules apply to everyone immediately"

Fact: The March 10, 2025 criteria changes only affect new authorization requests. If you already have an approved authorization for Ocrevus, the new step therapy requirements don't impact your current coverage.

Myth 4: "Primary progressive MS patients have the same requirements as relapsing MS"

Fact: Different rules apply. For primary progressive MS, you need a neurologist-confirmed diagnosis and must be under age 55. The step therapy requirements that apply to relapsing forms of MS don't apply to primary progressive MS patients.

Myth 5: "All Blue Cross Blue Shield plans have identical Ocrevus coverage"

Fact: Blue Cross Blue Shield operates as 33 independent plans across the country. While many share similar frameworks, your specific Washington plan may have unique requirements. Always verify with your individual plan.

Myth 6: "Insurance denials for Ocrevus are final"

Fact: Washington state provides robust appeal rights. You can pursue internal appeals through your plan, and if unsuccessful, request an Independent Review Organization (IRO) external review where an independent medical expert makes the final decision.

Myth 7: "The subcutaneous version (Ocrevus Zunovo) has different coverage rules"

Fact: Ocrevus Zunovo received FDA approval with the same indications as IV Ocrevus. Insurance coverage criteria typically apply equally to both formulations, though you should confirm with your specific plan.

What Actually Influences Approval

Clinical Documentation Requirements

Blue Cross Blue Shield Washington bases approval decisions on specific clinical criteria:

For Relapsing MS:

  • McDonald criteria-based diagnosis
  • Documentation of failure, contraindication, or intolerance to 2+ DMTs
  • Must include natalizumab and one additional agent
  • Clinical notes supporting treatment rationale

For Primary Progressive MS:

  • Neurologist-confirmed diagnosis
  • Patient age verification (under 55)
  • Clinical documentation of disease progression

Required Screening and Safety Measures

Before approval, insurers require documentation of:

Administrative Factors

Coverage decisions also depend on:

  • Completeness of prior authorization forms
  • Timely submission by healthcare providers
  • Proper coding (ICD-10, HCPCS, NDC numbers)
  • Clear treatment goals and monitoring plans

Avoid These Preventable Mistakes

1. Incomplete Step Therapy Documentation

The most common denial reason is insufficient documentation of prior DMT failures. Ensure your neurologist provides:

  • Specific medications tried with dates
  • Reasons for discontinuation (efficacy failure, side effects, contraindications)
  • Duration of each trial
  • Clinical outcomes and MRI progression data

2. Missing Safety Screening Results

Submit all required lab work with your initial authorization:

  • HBV surface antigen, core antibody, and surface antibody
  • Complete blood count with differential
  • Immunoglobulin levels (IgG, IgA, IgM)

3. Using Outdated Forms or Criteria

Insurance requirements change frequently. Always:

  • Download the most current prior authorization form
  • Verify current criteria with member services
  • Check for recent policy updates

4. Inadequate Medical Necessity Justification

Your neurologist's letter should clearly explain:

  • Why Ocrevus is medically necessary for your specific case
  • How previous treatments failed to control disease activity
  • Expected benefits and monitoring plan
  • Contraindications to alternative treatments

5. Missing Appeal Deadlines

Washington state provides 180 days from the final internal denial to request external review. Missing this deadline eliminates your appeal rights.

Quick Action Plan: Three Steps to Do Today

Step 1: Verify Your Coverage Details

Call the member services number on your Blue Cross Blue Shield card and ask:

  • "Does my plan require prior authorization for Ocrevus?"
  • "What is the current prior authorization form for Ocrevus?"
  • "What step therapy requirements apply to my plan?"

Step 2: Gather Your Treatment History

Compile documentation of:

  • All MS medications you've tried (names, dates, outcomes)
  • MRI reports showing disease activity
  • Lab results and vaccination records
  • Current neurologist's contact information

Step 3: Schedule a Strategy Session with Your Neurologist

Discuss:

  • Your treatment history and how it meets step therapy requirements
  • Timeline for prior authorization submission
  • Backup treatment options if initial request is denied
  • Appeal strategy if needed
From our advocates: We often see patients succeed on appeal after initial denials when they provide comprehensive documentation of DMT failures. One composite case involved a patient whose neurologist initially submitted minimal documentation about previous interferon therapy. After the denial, they resubmitted with detailed MRI progression data, side effect documentation, and clear contraindications to other DMTs. The appeal was approved within two weeks.

Appeals Process in Washington

If Blue Cross Blue Shield denies your Ocrevus authorization, Washington state provides strong consumer protections:

Internal Appeals (Required First Step)

  • Timeline: Submit within plan's specified timeframe (typically 60-180 days)
  • Process: Your plan reviews the denial with additional documentation
  • Duration: 30 days for standard review, 72 hours for expedited

External Review Through IRO

If internal appeals fail, you can request an Independent Review Organization review:

  • Timeline: 180 days from final internal denial
  • Process: Independent medical experts review your case
  • Cost: Free to you
  • Decision: Binding on the insurance plan

Consumer Advocacy Support

The Washington Office of the Insurance Commissioner provides free assistance:

  • Phone: 1-800-562-6900
  • Hours: 8:30 a.m. to 4:30 p.m., Monday-Friday
  • Services: Help with appeals, complaint filing, and understanding your rights

When appealing, Counterforce Health can help you build evidence-backed appeals that address specific denial reasons with targeted medical literature and policy analysis. Their platform specializes in turning insurance denials into successful authorizations by aligning clinical evidence with payer-specific requirements.

Resources and Forms

Official Blue Cross Blue Shield Resources

  • Member portal: Log in through your plan's website to check authorization status
  • Prior authorization forms: Available through provider portal (verify current version)
  • Customer service: Number on your insurance card

Washington State Resources

Clinical Resources

Professional Support

For complex cases requiring detailed appeal strategies, Counterforce Health offers specialized assistance in building evidence-based appeals that address specific payer criteria and denial reasons.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage varies by individual plan and circumstances. Always consult with your healthcare provider about treatment decisions and contact your insurance plan directly to verify current requirements and procedures.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.